Senores Pharmaceuticals IPO
- IPO Date20 Dec, 2024 to 24 Dec, 2024
- Listing Date30 Dec, 2024
- Face Value₹10 per share
- Issue Price₹372 to ₹391 per share
- Lot Size38 Shares
- Minimum Investment₹14,858
- Listing AtBSE, NSE
- Total Issue Size1,48,87,723 Shares
(aggregating up to ₹582.11 Cr) - Fresh Issue1,27,87,723 Shares
(aggregating up to ₹500.00 Cr)
- Offer for Sale21,00,000 Shares
(aggregating up to ₹82.11 Cr) - Issue TypeBook Built Issue IPO
- Share holding pre issue3,32,65,865
- Shareholding post issue4,60,53,588
IPO Dates
Closing Date
24 Dec, 2024
Initiation of Refunds
27 Dec, 2024
Listing Date
30 Dec, 2024
20 Dec, 2024
Opening Date
26 Dec, 2024
Basis of Allotment
27 Dec, 2024
Credit of Shares
Senores Pharmaceuticals Lot Size
Investors can bid for a minimum of 38 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Max) | 13 | 494 | ₹1,93,154 |
| S-HNI (Max) | 67 | 2546 | ₹9,95,486 |
| Retail (Min) | 1 | 38 | ₹14,858 |
| B-HNI (Min) | 68 | 2584 | ₹10,10,344 |
| S-HNI (Min) | 14 | 532 | ₹2,08,012 |
Senores Pharmaceuticals Promoter Holding
The promoters of the company are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot.
| Pre Issue Share Holding | Post Issue Share Holding |
|---|---|
| 71.1% | - |
Senores Pharmaceuticals COMPANY INFORMATION
Senores Pharmaceuticals IPO is a book built issue of Rs 582.11 crores. The issue is a combination of fresh issue of 1.28 crore shares aggregating to Rs 500.00 crores and offer for sale of 0.21 crore shares aggregating to Rs 82.11 crores. Senores Pharmaceuticals IPO opens for subscription on December 20, 2024 and closes on December 24, 2024. The allotment for the Senores Pharmaceuticals IPO is expected to be finalized on Thursday, December 26, 2024. Senores Pharmaceuticals IPO will list on BSE, NSE with tentative listing date fixed as Monday, December 30, 2024. Senores Pharmaceuticals IPO price band is set at ₹372 to ₹391 per share. The minimum lot size for an application is 38. The minimum amount of investment required by retail investors is ₹14,858. The minimum lot size investment for sNII is 14 lots (532 shares), amounting to ₹2,08,012, and for bNII, it is 68 lots (2,584 shares), amounting to ₹10,10,344. Equirus Capital Private Limited, Ambit Private Limited, Nuvama Wealth Management Limited are the book running lead managers of the Senores Pharmaceuticals IPO, while Link Intime India Private Ltd is the registrar for the issue. Refer to Senores Pharmaceuticals IPO RHP for detailed information.
Incorporated in December 2017, Senores Pharmaceuticals develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets.
The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets.
As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.
As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US.
The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs.
The company's manufacturing unit is situated in Ahmedabad, Gujrat.
Competitive Strength
- The company serves the US, Canada, and the UK regulated markets with its US FDA-approved manufacturing facility.
- A unique product portfolio tailored for regulated markets developed in a brief period.
- Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the United Kingdom regulated markets.
- Presence in the Emerging Markets with a product portfolio, including speciality or complex products.
- Robust R&D capabilities driving our differentiated portfolio of products.
- Experieced Management Team
FAQs About Senores Pharmaceuticals Ipo
Senores Pharmaceuticals IPO will open on 20 Dec, 2024 and close on 24 Dec, 2024. Investors must apply within this period to participate.
The Senores Pharmaceuticals IPO price band is set between ₹372.00 and ₹391.00 per share. The minimum lot size is 38, requiring an investment of at least ₹14858.00.
The Senores Pharmaceuticals IPO shares are expected to be listed on 30 Dec, 2024, subject to regulatory approvals and final allotment.
You can track your Senores Pharmaceuticals IPO application status on the registrar’s website: Link Intime or KFintech using your PAN, application number, or DP ID
The Senores Pharmaceuticals IPO will be listed on major stock exchanges such as NSE and BSE, where you can trade shares once they are listed.